Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

32.72
Delayed Data
As of 2:59pm ET
 -0.195 / -0.59%
Today’s Change
28.25
Today|||52-Week Range
36.46
+1.35%
Year-to-Date
What to Look For When Pfizer (PFE) Posts Q1 Results
1:04pm / TheStreet.com
ARIAD Gains on Updated Brigatinib Phase I/II Study Data
Apr 19 / Zacks.com
3 Drug Stocks Reporting Early Next Week: PFE, MYL, MNK
11:07am / Zacks.com
15 Reasons to Buy Pfizer and Never Sell
Apr 15 / MotleyFool.com
Sanofi First Quarter Shows Why it Wants but Doesn't Need Medivation
6:25am / TheStreet.com
Allergan's Credit Rating Appears Safe -- Is Its Stock?
Apr 14 / MotleyFool.com
Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Apr 28 / Zacks.com
Top 50 U.S. companies hold $1.4 trillion in cash offshore
Apr 14 / CNNMoney.com
Pfizer (PFE) to Report Q1 Earnings: Will the Stock Surprise?
Apr 28 / Zacks.com
Microsoft Has More of Its Money Abroad Than Apple
Apr 13 / MotleyFool.com
UnitedHealths Obamacare Changes to Affect Healthcare Sector
Apr 27 / GuruFocus News
Companies cannot escape nationalities and borders
Apr 13 / FT.com
Daniel Loeb warns of hedge fund 'killing field'
Apr 27 / FT.com
Peering Into Allergan's Post-Pfizer Future
Apr 12 / MotleyFool.com
Tax Inversions: Explaining What They Are, How We Got Here and What's Next
Apr 26 / TheStreet.com
Pfizer Inc's Unspoken Message To Investors: It Was Always About Taxes
Apr 12 / MotleyFool.com
Will the Next President Be as Tough on Mergers and Acquisitions as Obama?
Apr 26 / TheStreet.com
Stock Market News for April 12, 2016
Apr 12 / Zacks.com
Treasury Department Was 'Targeting' Pfizer-Allergan Deal
Apr 26 / TheStreet.com
Local politics can turn deal heroes to zeros
Apr 11 / FT.com
With New Treasury Department Rules, Is This the End of Tax Inversion Deals?
Apr 26 / TheStreet.com
M&A crackdown puts bond investors on edge
Apr 11 / FT.com
Is Now the Time to Jump on Allergan?
Apr 25 / TheStreet.com
M&A splurge comes home to roost
Apr 08 / FT.com
Healthcare Q1 Earnings Look Solid: ETFs to Benefit
Apr 25 / Zacks.com
M&A deals worth $370bn torpedoed by Obama administration
Apr 07 / FT.com
Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings
Apr 25 / TheStreet.com
Pfizer chief's long quest for tax inversion ends in failure
Apr 06 / FT.com
Vaccine development needs global alliance
Apr 24 / FT.com
M&A failures: deep breaths
Apr 06 / FT.com
Vaccines are among big pharma's best-selling products
Apr 24 / FT.com
US Treasury shatters Pfizer chief Ian Read's merger dreams
Apr 06 / FT.com
Does Biotechs Recent Bounce Have Legs?
Apr 22 / GuruFocus News
Big pharma seeks digital solution to productivity problem
Apr 06 / FT.com
3 Stocks We're Ready to Buy Again
Apr 22 / MotleyFool.com
Pfizer merger collapse is serious failure of management
Apr 06 / FT.com
Better Buy: Pfizer Inc. vs. AbbVie
Apr 21 / MotleyFool.com
Pfizer: plan C
Apr 06 / FT.com
Pfizer Reports Positive Data on Breast Cancer Drug Ibrance
Apr 20 / Zacks.com
Pfizer-Allergan merger scrapped after Obama cracks down on tax breaks
Apr 06 / CNNMoney.com
3 Value Stocks Near 52-Week Lows Worth Buying
Apr 20 / MotleyFool.com
Stocks: 5 things to know before the open
Apr 06 / CNNMoney.com
Johnson & Johnson Boosts Guidance on Strong 1st-Quarter Results
Apr 19 / MotleyFool.com
Pfizer and Allergan abandon $160bn deal after US tax crackdown
Apr 06 / FT.com
Paulson's funds plunge nearly $2bn on Allergan and Valeant bets
Apr 19 / FT.com
US tax crackdown provokes foreign fury
Apr 05 / FT.com
Synergy Pharmaceuticals Soars After FDA Filing Accepted
Apr 19 / TheStreet.com
US crackdown on inversions came 'out of left field'
Apr 05 / FT.com
Will Weak Alcon Sales Hurt Novartis' (NVS) Q1 Earnings?
Apr 19 / Zacks.com
Treasury's shot at tax inversions will cause collateral damage
Apr 05 / FT.com